Besides, our previous study demonstrated that Akt-specific inhibitor MK2206, a clinical phase II drug, showed an anti-atherosclerosis activity in vitro and in vivo, and it reduced plasma-CCL2 levels in ApoE−/− mice (28). Here, CCL2 is linked to atherosclerosis.